ASX Filings

Response to ASX Query

February 16, 2023

Opthea Ph2b Trial Results with OPT-302 published in Journal

February 14, 2023

Appendix 2A

February 10, 2023

Opthea to present at SVB Leerink Global Biopharma Conference

February 7, 2023

Opthea to Present at Sequire Biotechnology Conference

January 31, 2023

Ceasing to be a substantial holder

January 28, 2023

Opthea Corporate Presentation - San Francisco Jan 2023

January 11, 2023

Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

December 12, 2022

Additional Formats

PDF Version

Opthea to present at the FLORetina 2022 Congress

December 6, 2022

Additional Formats

PDF Version

Cleansing Notice

November 30, 2022